Pharmaceuticals
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo
HANGZHOU, China, SHANGHAI and BOSTON, July 9, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the first patient was successfully dosed on June 30 in...
2026-07-09 08:00
3664
On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations
SAN DIEGO , July 8, 2026 /PRNewswire/ -- On the eve of the highly anticipated BIO International Convention 2026, theBIOSeedin Summer Innovation Partnering Summit successfully took place in San Diego. Hosted by bioSeedin and proudly supported by strategic partners Thermo Fisher Scientific and ACRO...
2026-07-09 00:00
2446
Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026
MONTPELLIER, France, July 8, 2026 /PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading conferences dedicated to therapeutic antibodies and biotherapeutics. At the event, the company...
2026-07-08 22:17
2723
Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
* First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing. * Demonstrated a unified quality system, strict risk assessment protocols, and compliance with rigorous regulatory requirements from development through commercialization. HA...
2026-07-08 22:00
3348
Seegene Launches Industry's First Global Million Clinical Study to Shape New Disease-Specific Testing Standards
* Seegene is launching the Global Million Clinical Study at the scale of one million test cases to shape disease-specific testing standards. * The study is designed to evaluate the clinical utility of syndromic PCR testing approaches and build real-world scientific evidence to support better-...
2026-07-08 21:00
3015
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
* Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026) * Included in the MSCI ESG Selection Indexes for the fourth consecutive year * Leader in Green CRDMO solutions for a healthier future SHANGHAI, July 8, 2026 /PRNewswire/ -- WuXi Bi...
2026-07-08 15:15
4733
Wegovy® (semaglutide) label updated in Singapore with higher dose supported by STEP UP evidence
* Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks * Mean weight loss with semaglutide 7.2 mg reached 21%, reflecting overall treatment efficacy * Up to 84% of weight loss was driven by reductions in fat mass, supporting meaningful improv...
2026-07-08 09:22
2586
Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
* Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature Medicine * Rentosertib represents a novel mec...
2026-07-07 21:43
4100
Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
MUMBAI, India, July 7, 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capab...
2026-07-07 20:50
4222
Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma
EAST RUTHERFORD, N.J., July 7, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), proudly announces that Snapdragon Chemistry, a Cambrex company, together with NewAmsterdam Pharma, has received the American Chemical Society's 2026 Green Chem...
2026-07-07 20:00
2955
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
SHANGHAI, July 7, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the closing of its previously announc...
2026-07-07 18:53
3031
Ascletis Submits Two IND Applications to U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
- ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR. - ASC36_35 FDC demonstrated approximately 51% greater relative body weight reducti...
2026-07-06 08:10
3977
Strategic Collaboration | Sanyou Bio and Baiyunshan Xihe Join Forces to Advance Innovative Radiopharmaceuticals and Radiodiagnostics
SHANGHAI and GUANGZHOU, China, July 4, 2026 /PRNewswire/ -- Sanyou Biopharmaceutical Co., Ltd. ("Sanyou Bio") and Guangzhou Baiyunshan Xihe Health Pharmaceutical Co., Ltd. ("Baiyunshan Xihe") jointly announced the official signing of a strategic cooperation agreement. This partnership will focus ...
2026-07-04 23:25
6894
Shanghai SinoUnited Hospital Announced Availability of World's First CAR-T Therapy for Solid Tumors in Advanced Gastric Cancer
SHANGHAI, July 3, 2026 /PRNewswire/ -- Shanghai SinoUnited Hospital today announced the availability of satricabtagene autoleucel ("satri-cel"), the world's first chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of solid tumors, for eligible patients with Claudin18.2-posi...
2026-07-03 13:36
4959
Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence
CAMBRIDGE, Mass., July 2, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the appointment of Dr. Peng Wang as Chief Operating Officer (COO). Dr. Wang will be...
2026-07-03 09:36
3747
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
* End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategies * End-of-treatment data from ENHANCE did not demonstrate improved HBsAg loss rates compared to ...
2026-07-03 08:00
4578
SK bioscience Launches AI-Powered Initiative to Reduce Uncertainty in Vaccine-Development Decisions
* SK bioscience was selected to lead the Gates Foundation-funded ROTOR project, establishing a global collaboration framework. * SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making. * The project will supp...
2026-07-02 20:00
3316
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration a...
2026-07-02 10:16
3583
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
SUZHOU, China and MÖLNDAL, Sweden, July 2, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the successful...
2026-07-02 09:29
3018
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel I...
2026-07-02 09:00
3108
Week's Top Stories
Most Reposted
DBS crowned Southeast Asia's most valuable brand in Kantar BrandZ 2026 ranking
[Picked up by 308 media titles]
2026-07-15 12:00
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
[Picked up by 305 media titles]
2026-07-16 10:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 295 media titles]
2026-07-20 15:00
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
[Picked up by 291 media titles]
2026-07-17 18:18
Klook signs an expanded two-year partnership with Korea Tourism Organization
[Picked up by 288 media titles]
2026-07-16 17:49
Most Read
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
2026-07-16 10:00
14926
DBS crowned Southeast Asia's most valuable brand in Kantar BrandZ 2026 ranking
2026-07-15 12:00
11563
Klook signs an expanded two-year partnership with Korea Tourism Organization
2026-07-16 17:49
10513